Retrospective study of vigabatrin and psychiatric behavioural disturbances

Epilepsy Res. 1995 Jul;21(3):227-30. doi: 10.1016/0920-1211(95)00022-3.

Abstract

Vigabatrin (VGB) is an effective add-on anti-epileptic drug. The major serious adverse drug reactions (ADRs) are behavioural and psychiatric disturbances. This study does not support the view that a previous history of behavioural and psychiatric features increases the risk of behavioural/psychiatric ADRs (relative risk 1.23, 95% CI 0.57-2.66, P = 0.61). The results suggest that a low starting does of vigabatrin does not reduce the risk of psychiatric and behavioural ADRs (P = 0.31) or prevent a more overt psychotic reaction from occurring.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anticonvulsants / adverse effects*
  • Anticonvulsants / therapeutic use*
  • Child
  • Epilepsy / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Mental Disorders / chemically induced
  • Mental Disorders / epidemiology*
  • Middle Aged
  • Retrospective Studies
  • Vigabatrin
  • gamma-Aminobutyric Acid / adverse effects
  • gamma-Aminobutyric Acid / analogs & derivatives*
  • gamma-Aminobutyric Acid / therapeutic use

Substances

  • Anticonvulsants
  • gamma-Aminobutyric Acid
  • Vigabatrin